In a significant leap forward for the integration of artificial intelligence in medicine, Deep Origin and BioAge Labs have announced a strategic, multi-target partnership aimed at accelerating the discovery of novel therapeutics. The collaboration has already hit the ground running, successfully validating its first milestone: the identification and wet-lab confirmation of small-molecule hits against a challenging new biological target.
BioAge Labs, a clinical-stage biopharmaceutical firm, is widely recognized for its work in cardiometabolic disease, specifically targeting the molecular underpinnings of human aging. By utilizing unique human data sets derived from longitudinal studies, BioAge identifies novel drug targets that are often difficult to address with conventional chemistry.
The partnership leverages Deep Origin’s proprietary computational platform, which utilizes a hybrid approach combining advanced AI with physics-based models. This technical synergy is designed to bypass the traditional, time-consuming bottlenecks of early-stage drug discovery. According to the companies, this methodology allowed the team to deliver several structurally distinct, high-quality chemical hits in under three months—a timeframe substantially faster than standard industry benchmarks. BioAge has since moved this first target into the hit-to-lead optimization phase.
“BioAge finds its targets in human data, from people followed for decades,” said Michael Antonov, Co-Founder and CEO of Deep Origin. “Many are novel targets with little known chemistry. This is exactly the problem our virtual screening was built to solve.”
Antonov emphasized the rigorous standards held by BioAge’s internal chemistry teams, noting that the hits provided by his firm offer the “strong starting points” necessary to streamline the development process. For Deep Origin, the success of this collaboration represents a significant commercial opportunity, as the company is set to receive milestone payments tied to the continued progress and success of the programs.
Kristen Fortney, PhD, Co-Founder and CEO of BioAge, echoed these sentiments, highlighting how the partnership bridges the gap between raw biological insight and actionable medicine. “AI can help shorten the path from human biology to new medicines,” Fortney said. “Deep Origin’s platform delivered high-quality chemical matter against a novel target in just months. We’re thrilled with what we’ve accomplished together so far and look forward to extending the work to additional targets.”
As the biotech industry increasingly turns toward digital-first R&D, this partnership serves as a validation of the “AI-in-the-loop” model. By combining BioAge’s unique access to longevity-focused human data with the high-velocity computational power of Deep Origin, the two companies are positioning themselves to tackle some of the most complex challenges in cardiometabolic medicine. With the first milestone now secured, both firms are expected to expand their collaboration, aiming to replicate this rapid discovery cadence across a broader range of therapeutic targets.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
